Bone Marrow-Derived Mesenchymal Stem Cells; Normal, Human (ATCC® PCS-500-012)

Organism: Homo sapiens, human  /  Tissue: Bone  /  Cell Type: Mesenchymal Stem

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue Bone
Cell Type Mesenchymal Stem
Morphology spindle shaped, fibroblast-like
Growth Properties adherent
Biosafety Level 1 [These primary cells are not known to harbor an agent recognized to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. Cells derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens. 

ATCC recommends that appropriate safety procedures be used when handling all primary cells and cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures are provided in Laboratory Safety: Principles and Practice, 2nd ed. (ASM Press, Washington, DC) (Fleming et al., 1995) and Caputo, J.L. Biosafety procedures in cell culture. (1988) J. Tissue Culture Methods 11:223. Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online at] 

Human Material Precaution 

All tissues used for isolation are obtained under informed consent and conform to HIPAA standards to protect the privacy of the donor’s personal health information. It is best to use caution when handling any human cells. We recommend that all human cells be accorded the same level of biosafety consideration as cells known to carry HIV. With infectious virus assays or viral antigen assays, even a negative test result may leave open the possible existence of a latent viral genome.

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Normal
Age adult
Gender lot-specific
Ethnicity lot-specific
Applications Adult stem cell differentiation, regenerative medicine, cell therapy, tissue engineering, generation of iPS cell lines
Product Format frozen 1 mL
Storage Conditions -130°C or below
Comments The cells are cryopreserved in the second passage to ensure the highest viability and plating efficiency.

Mesenchymal Stem Cell Basal Medium, when supplemented with Mesenchymal Stem Cell Growth Kit – for Bone Marrow Derived MSCs, provides an ideal cell system to propagate mesenchymal stem cells. When maintained under optimal growth conditions, ATCC Normal Human Bone Marrow-Derived Mesenchymal Stem Cells have been shown to be multipotent, capable of differentiating down the adipogenic, osteogenic and chondrogenic lineages.
Complete Growth Medium
  1. Obtain one Mesenchymal Stem Cell Growth for Bone Marrow-derived MSCs (ATCC PCS-500-041) from the freezer; make sure that the caps of all components are tight.
  2. Thaw the components of the growth kit just prior to adding them to the basal medium (ATCC PCS-500-030).
  3. Obtain one bottle of Mesenchymal Stem Cell Basal Medium (485 mL) from cold storage.
  4. Decontaminate the external surfaces of all growth kit component vials and the basal medium bottle by spraying them with 70% ethanol.
  5. Using aseptic technique and working in a laminar flow hood or biosafety cabinet, transfer the indicated volume of each growth kit component, as indicated in Table 1, to the bottle of basal medium using a separate sterile pipette for each transfer.

Table 1. Bone Marrow-Mesenchymal Stem Cell Growth Kit Components



Final Concentration


35 mL


rh IGF-1

0.5 mL

2.4 mM

Rh FGF-b

0.5 mL

5 ng/mL


6 mL

2.4 mM

Antimicrobials and phenol red are not required for proliferation but may be added if desired. The recommended volume of either of the optional components (GA solution or PSA solution) to be added to the complete growth media is summarized in Table 2.

Table 2. Addition of Antimicrobials/Antimycotics and Phenol Red (Optional)



Final Concentration

Gentamicin-Amphotericin B Solution

0.5 mL

Gentamicin: 10 µg/mL

Amphotericin B: 25 ng/mL

Penicillin-Streptomycin-Amphotericin B Solution

0.5 mL

Penicillin: 10 Units/mL

Streptomycin: 10 µg/mL

Amphotericin B: 25 ng/mL

Phenol Red

0.5 mL

33 µM

  1. Tightly cap the bottle of complete growth medium and swirl the contents gently to assure a homogeneous solution. Do not shake forcefully to avoid foaming. Label and date the bottle.
  2. Complete growth media should be stored in the dark at 2°C to 8°C (do not freeze). When stored under these conditions, complete growth media is stable for two weeks.
  1. Passage normal BM-MSCs when the culture has reached approximately 80% confluence.
  2. Warm both the Trypsin-EDTA for Primary Cells (ATCC PCS-999-003) and the Trypsin Neutralizing Solution (ATCC PCS-999-004) to room temperature prior to dissociation. Warm the complete growth medium to 37°C prior to use with the cells.
  3. For each flask, carefully aspirate the spent media without disturbing the monolayer.
  4. Rinse the cell layer one time with 3 to 5 mL D-PBS (ATCC 30-2200) to remove residual medium.
  5. Add prewarmed trypsin-EDTA solution (1 to 2 mL for every 25 cm2) to each flask.
  6. Gently rock each flask to ensure complete coverage of the trypsin-EDTA solution over the cells.
  7. Observe the cells under the microscope. When the cells pull away from each other and round up (typically within 1 to 3 minutes), remove the flask from the microscope and gently tap it from several sides to promote detachment of the cells from the flask surface.
  8. When the majority of cells appear to have detached, quickly add an equal volume of the Trypsin Neutralizing Solution (ATCC PCS-999-004) to each flask. Gently pipette or swirl the culture to ensure all of the trypsin-EDTA solution has been neutralized.
  9. Transfer the dissociated cells to a sterile centrifuge tube and set aside while processing any remaining cells in the culture flask.
  10. Add 3 to 5 mL D-PBS (ATCC 30-2200) to the tissue culture flask to collect any additional cells that might have been left behind.
  11. Transfer the cell/D-PBS suspension to the centrifuge tube containing the trypsin-EDTA dissociated cells.
  12. Repeat steps 10 and 11 as needed until all cells have been collected from the flask.
  13. Centrifuge the cells at 270 x g for 5 minutes.
  14. Aspirate neutralized dissociation solution from the cell pellet and resuspend the cells in 2 to 8 mL fresh, prewarmed, complete growth medium.
  15. Count the cells and seed new culture flasks at a density of 5,000 viable cells per cm2.
  16. Place newly seeded flasks in a 37°C, 5% CO2 incubator for at least 24 to 48 hours before processing the cells further. Refer to Maintenance for guidelines on feeding.
Volume 1 mL
Cells per Vial One vial contains a minimum of 1 x 106 viable cells.
Sterility Tests Bacteria and Yeast: Negative
Mycoplasma: Negative
Viral Testing Hepatitis B: Negative
Hepatitis C: Negative
HIV: Negative
Viability ≥ 70% when thawed from cryopreservation
Population Doubling Capacity ≥ 10 in complete growth medium
C of A
Certificate of Analysis
Certificate of Analysis
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

Al Madhoun A, et al. Chemically Defined Conditions Mediate an Efficient Induction of Mesodermal Lineage from Human Umbilical Cord- and Bone Marrow- Mesenchymal Stem Cells and Dental Pulp Pluripotent-Like Stem Cells. Cell Reprogram 20(1):9-16, 2018. PubMed: 29412734

Zheng B, et al. Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo. Theranostics 6(3):291-301, 2016. PubMed: 26909106

Wang M, et al. Cold atmospheric plasma (CAP) surface nanomodified 3D printed polylactic acid (PLA) scaffoldsfor bone regeneration. Acta Biomater 46:256-265, 2016. PubMed: 27667017

Liu CJ, et al. Suppression of IL-8-Src signalling axis by 17β-estradiol inhibits human mesenchymal stem cells-mediated gastric cancer invasion. J Cell Mol Med 20(5):962-72, 2016. PubMed: 26945908

Khalil S, et al. A Cost-Effective Method to Assemble Biomimetic 3D Cell Culture Platforms. PLoS One 11(12):e0167116, 2016. PubMed: 27935982

Zhou C, et al. INO80 is Required for Osteogenic Differentiation of Human Mesenchymal Stem Cells. Sci Rep 6:35924, 2016. PubMed: 27804957

Chen K, et al, Human MSCs promotes colorectal cancer epithelial-mesenchymal transition and progression viaCCL5/β-catenin/Slug pathway. Cell Death Dis 8(5):e2819, 2017. PubMed: 28542126